Lomeguatrib
-
Lomeguatrib
structure -
-
CAS No:
192441-08-0
-
Formula:
C10H8BrN5OS
-
Chemical Name:
Lomeguatrib
-
Synonyms:
9H-Purin-2-amine,6-[(4-bromo-2-thienyl)methoxy]-;1H-Purin-2-amine,6-[(4-bromo-2-thienyl)methoxy]-;6-[(4-Bromo-2-thienyl)methoxy]-9H-purin-2-amine;Lomeguatrib;2-Amino-6-(4-bromothiophen-2-ylmethoxy)-9H-purine;PaTrin 2;793035-44-6
- Categories:
-
CAS No:
Description
Lomeguatrib is a O6-methylguanine-DNA methyltransferase (MGMT) inhibitor, with IC50s of 9 nM in cell-free assay and ∼6 nM in MCF-7 cells.
Characteristics
118
2
white to beige
2.07
683.8°C at 760 mmHg
367.3±34.3 °C
1.797
DMSO: soluble10mg/mL, clear
room temp
Safety Information
NONH for all modes of transport
3
22
UO7420000
Xn
P264, P270, P301+P312, P330, P501
H302
Lomeguatrib Use and Manufacturing
O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein which removes an alkyl group from the O6 position on guanine in an autoinactivating reaction. Although important in normal DNA repair, this reaction confers resistance to treatments that use O6-alkylating agents to produce cytotoxicity, e.g., in cancer. Lomeguatrib is a modified quanine base which acts as a pseudosubstrate inactivator of MGMT (IC50 = ~3 nM). A non-toxic compound, lomeguatrib completely inactivates MGMT in human prostate and colorectal tumors when given as a single 120 mg oral dose and in primary central nervous system cancers at 160 mg.
Computed Properties
Molecular Weight:326.17
XLogP3:2
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:3
Exact Mass:324.96329
Monoisotopic Mass:324.96329
Topological Polar Surface Area:118
Heavy Atom Count:18
Complexity:299
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of Lomeguatrib
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
US
6 YRS
Business licensed Certified factoryManufactory Supplier of Coenzymes,Inhibito,Enzymes,Zymogens,Substrates
Latest News on Lomeguatrib
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4